Table 2.
Time course of composite measures and remission rate stratified by DAS28 (ESR) at discontinuation of ADA
|
DAS28 (ESR) ≤2.16 at discontinuation (n = 32) |
2.16 <DAS28 (ESR) <2.6 at discontinuation (n = 18) |
|||||||
|---|---|---|---|---|---|---|---|---|
|
Week 0 |
Week 24 |
Week 0 |
Week 24 |
|||||
| mean ± SD | median (IQR) | mean ± SD | median (IQR) | mean ± SD | median (IQR) | mean ± SD | median (IQR) | |
| TJC28 |
0.06 ± 0.25 |
0 (0, 0) |
1.28 ± 3.27 |
0 (0, 1) |
0.22 ± 0.55 |
0 (0, 0) |
1.39 ± 2.09 |
0 (0, 2.5) |
| SJC28 |
0.03 ± 1.77 |
0 (0, 0) |
0.41 ± 0.98 |
0 (0, 0) |
0.0 ± 0.0 |
0 (0, 0) |
1.17 ± 2.33 |
0 (0, 1) |
| PGA (mm) |
5.41 ± 6.38 |
2 (0, 10) |
9.75 ± 12.15 |
4.5 (0.3, 15.8) |
8.72 ± 15.08 |
4 (1.5, 7.5) |
16.17 ± 23.63 |
5 (0.75, 27) |
| EGA (mm) |
2.25 ± 3.62 |
1 (0, 2.8) |
7.22 ± 12.13 |
1.5 (0, 9.5) |
2.50 ± 3.07 |
2 (0, 3.25) |
10.72 ± 16.57 |
5.5 (0, 10.5) |
| ESR (mm/hr) |
9.78 ± 4.11 |
9 (6.3, 12) |
15.78 ± 10.07 |
14 (10, 18.8) |
24.39 ± 9.05 |
24.5 (17.5, 32) |
39.33 ± 20.55 |
37 (21.5, 53.75) |
| CRP (mg/dl) |
0.11 ± 0.17 |
0.04 (0.01, 0.11) |
0.35 ± 0.65 |
0.1 (0.05, 0.30) |
0.11 ± 0.22 |
0.04 (0.03, 0.08) |
0.22 ± 0.23 |
0.15 (0.04, 0.2) |
| CDAI |
0.86 ± 1.00 |
0.4 (0.03, 1.5) |
3.38 ± 5.95 |
1.0 (0.1, 3.0) |
1.34 ± 1.83 |
0.6 (0.275, 1.7) |
5.24 ± 7.32 |
2.2 (0.075, 9.2) |
| SDAI |
0.97 ± 1.01 |
0.45 (0.2, 1.8) |
3.74 ± 6.23 |
1.1 (0.3, 4.2) |
1.44 ± 1.81 |
0.8 (0.3, 1.775) |
5.45 ± 7.37 |
2.55 (0.275, 0.2)] |
| DAS28 (ESR) |
1.65 ± 0.34 |
1.70 (1.45, 2.00) |
2.30 ± 1.11 |
2.00 (1.80, 2.43) |
2.41 ± 0.15 |
2.46 (2.27, 2.54) |
3.24 ± 1.14 |
2.78 (2.54, 3.64) |
| HAQ |
0.14 ± 0.23 |
0 (0, 0.3) |
0.18 ± 0.39 |
0 (0, 0.1) |
0.38 ± 0.38 |
0.31 (0, 0.66) |
0.40 ± 0.44 |
0.25 (0, 0.78) |
| mTSS |
27.86 ± 61.96 |
8 (2.5, 23) |
|
|
64.41 ± 111.33 |
9 (0.5, 88) |
|
|
| |
n/N |
percent |
n/N |
percent |
n/N |
percent |
n/N |
percent |
| DAS28 (ESR) <2.6 |
32/32 |
100% |
25/32 |
78.1% |
18/18 |
100% |
4/18 |
22.2% |
| DAS28 (ESR) <3.2 |
32/32 |
100% |
27/32 |
84.4% |
18/18 |
100% |
11/18 |
61.1% |
| CDAI ≤2.8 |
31/32 |
96.9% |
24/32 |
75.0% |
15/18 |
83.3% |
11/18 |
61.1% |
| SDAI ≤3.3 |
31/32 |
96.9% |
23/32 |
71.9% |
15/18 |
83.3% |
11/18 |
61.1% |
| Boolean definition | 25/32 | 78.1% | 21/32 | 65.6% | 15/18 | 83.3% | 10/18 | 55.6% |
CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28 (ESR), disease activity score by using 28 joints based on erythrocyte sedimentation rate; EGA, evaluator’s global assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LOCF, last observation carried forward; mTSS, modified total Sharp score, Boolean definition: ACR/EULAR 2010 definition criteria of clinical remission (TJC ≤1, SJC ≤1, PGA ≤1 cm, CRP ≤1 mg/dl); PGA, patient’s global assessment; SDAI, simplified disease activity index; SJC, swollen joint count; TJC, tender joint count.